Sep 2026· Trends in Cancer· 0 citations· 99 references
Medicine
TL;DR
This review summarizes RBM15 structure, function, and regulation, and highlights its emerging roles in leukemia, including AMKL and myelodysplastic syndromes, while outlining key questions for future studies.
Abstract
RNA-binding motif protein 15 (RBM15) is a key regulator of hematopoiesis and leukemogenesis, linking RNA metabolism, epitranscriptomic regulation, and lineage specification. Identified through the RBM15::MKL1 fusion in acute megakaryoblastic leukemia (AMKL), RBM15 functions within the N6-methyladenosine (m6A) writer complex, where its RNA-recognition motifs and SPOC domain enable site-specific methylation and protein recruitment. In hematopoietic stem and progenitor cells (HSPCs), RBM15 supports stem cell quiescence, self-renewal, and balanced lineage output, with additional roles in B-cell, myeloid, and megakaryocytic differentiation. Mechanistically, RBM15 links m6A deposition to chromatin regulation, RNA export, and splicing. This review summarizes RBM15 structure, function, and regulation, and highlights its emerging roles in leukemia, including AMKL and myelodysplastic syndromes, while outlining key questions for future studies.
It is found that in adult human HSPC, BRD9 regulates the differentiation of myeloid progenitors, and loss of BRD9 results in increased cBAF recruitment to CEBPA target sites and enhanced myeloid differentiation.
Emmalee R. Adelman, Adedamola A. Adele, Caio Ricardo Gutierrez Silva et al.· bioRxiv· 0 citations
PTBP1 is established as a critical regulator of AML cell fitness and a clinically actionable therapeutic combination that exploits AML dependency on PTBP1-CDC42 signaling to enhance the efficacy of venetoclax-based regimens is identified.
DNA-proximal phosphorylation of MYB is identified as a critical regulatory mechanism required for MYB oncogenesis through cooperative organization of transcription factors and nominated MYB N-terminal phosphorylation and its upstream kinases as candidate therapeutic targets for MYB-dependent leukemia.
Shu-Yuan Cheng, Katarzyna Kulej, Masahiro Uni et al.· Cancer Research· 0 citations
SDRNAs are introduced as standalone regulatory effector molecules in healthy hematopoiesis and AML and proposed and characterized NUDT21, an important regulator of alternative polyadenylation and oncogenic gene expression, as a downstream target of sd3'-SNORD78 in AML.
R. Zinz, Christian Rohde, C. Pauli et al.· Leukemia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.